HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Clarins

This article was originally published in The Rose Sheet

Executive Summary

Net profit rose 11.2% at constant exchange rates to $116.4 mil. (€1=$1.20) in 2005, due in part to "a sharp decrease in net interest expense as a result of...debt reduction," in addition to a reduction in average current tax rate and unrealized gains from its stake in L'Occitane, French beauty firm reports March 24. Net profit was up 11.4% on a like-for-like basis. Operating profit rose 4.5% to $152.1 mil. Clarins' Beauty operating profit advanced 9.4%, or 9% like-for-like, to $112.5 mil. during the year, while Perfumes division operating profit declined 7.3%, or 6.4% on a like-for-like basis, to $39.6 mil. Clarins reported 2005 net sales in February (1"The Rose Sheet" Feb. 6, 2006, p. 6)...

You may also be interested in...



Clarins Will Step Up Skin Care Offerings To Grow Segment In ’06

Clarins is targeting its skin care business as a primary area of growth this year, the French beauty firm announced in a Feb. 3 sales release

GermBloc Hand-Sanitizer Class Action Takes Aim At 99.99% Germ-Killing Claim

Like other hand sanitizer manufacturers, WillSpeed Technology claims its GermBloc “kills 99.99% of germs.” Plaintiffs in a proposed class action filed in Massachusetts federal court allege the claim “grossly overstates” the product’s efficacy, deceiving consumers and endangering them with false confidence.

Keeping Track: US FDA Set For Speed With Approvals Of Inqovy, Rukobia, Dojolvy, Phesgo; Keytruda Loses Chance At AA In HCC

The latest drug development news and highlights from the Pink Sheet’s FDA Performance Tracker.

UsernamePublicRestriction

Register

LL1128165

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel